IRIS
RUPERTO, NICOLINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.780
AS - Asia 29
SA - Sud America 10
NA - Nord America 2
Totale 5.821
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 5.780
CN - Cina 24
BR - Brasile 10
VN - Vietnam 4
US - Stati Uniti d'America 2
SG - Singapore 1
Totale 5.821
Salva come PNG Salva come JPEG
Città #
Genova 3.001
Genoa 1.766
Rapallo 527
Vado Ligure 473
Beijing 14
Bordighera 12
Ashburn 2
Hanoi 2
Ho Chi Minh City 2
Carapicuíba 1
Caxias do Sul 1
Conselheiro Lafaiete 1
Curitiba 1
Ipu 1
Juiz de Fora 1
Mauá 1
Santo André 1
Singapore 1
Sumaré 1
Várzea Grande 1
Totale 5.810
Salva come PNG Salva come JPEG
Nome #
A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis 185
Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome 164
2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative 164
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 158
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 153
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects 153
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept 152
Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 151
Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis 149
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation collaborative initiative 147
Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. 144
Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study 142
Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care 142
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 133
A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry 133
Development and validation of a composite disease activity score for juvenile idiopathic arthritis 129
Clinical trials in children and adolescents with systemic lupus erythematosus: Methodological aspects, regulatory landscape and future opportunities 124
The Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 122
Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study. 118
The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set. 116
Performance of different diagnostic criteria for familial Mediterranean fever in children with periodic fevers: Results from a multicenter international registry 116
Tapering Canakinumab Monotherapy in Patients with Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results from an Open‐label, Randomized Phase IIIb/IV Study 114
American College of Rheumatology Provisional Criteria for Global Flares in Childhood-Onset Systemic Lupus Erythematosus 110
An international delphi survey for the definition of the variables for the development of new classification criteria for periodic fever aphtous stomatitis pharingitis cervical adenitis (PFAPA) 110
Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy 107
Current and future perspectives in the management of juvenile idiopathic arthritis 101
Treatment of juvenile idiopathic arthritis: what's new? 100
Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study 100
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 98
The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry 98
Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative 97
The PRINTO juvenile dermatomyositis trial - Authors' reply 97
Treating juvenile idiopathic arthritis to target: Recommendations of an international task force 95
Current medical treatments for juvenile idiopathic arthritis 94
The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry 93
Health-related quality of life of patients with juvenile idiopathic arthritis coming from 3 different geographic areas. The PRINTO multinational quality of life cohort study 93
Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: Results from the 5-year long-term extension of the phase III pivotal trials 88
Measuring Disease Damage and Its Severity in Childhood-Onset Systemic Lupus Erythematosus 88
Development and testing of reduced versions of the MMT-8 in juvenile dermatomyositis 87
Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: Results of a multicentre, double-blind, randomised-withdrawal trial 84
Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus 83
A clinical prediction model for estimating the risk of developing uveitis in patients with juvenile idiopathic arthritis 79
Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitisrelated arthritis, or psoriatic arthritis 75
Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: Results of a phase 1, open-label, multicenter study 75
International consensus for a definition of disease flare in lupus 75
Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis 73
Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: Post hoc radiographic analysis from two randomized controlled trials 72
Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial 71
Extrapolation or controlled trials in paediatrics: The current dilemma 67
Disease activity, overweight, physical activity and screen time in a cohort of patients with juvenile idiopathic arthritis 61
Development and initial validation of parent and child versions of the Juvenile Arthritis Disease Activity Score 58
Is it worth including subtalar joint in ultrasound ankle assessment of patients with juvenile idiopathic arthritis? 51
Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the "comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS" (STARS) trial 50
Preface 45
Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index 43
Outcome Scores in Pediatric Rheumatology 42
Validity and Reliability of Four Parent/Patient-Reported Outcome Measures for Juvenile Idiopathic Arthritis Remote Monitoring 41
Validation of the PEDiatric Behçet’s Disease classification criteria: an evidence-based approach 33
Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers 27
Paediatric rheumatologists do not score the physician's global assessment of juvenile idiopathic arthritis disease activity in the same way 23
Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study 17
Totale 6.010
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.282
article - articoli 23.282
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.564
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021410 0 0 0 0 24 30 72 60 31 110 19 64
2021/2022662 65 32 30 56 14 62 19 136 61 69 29 89
2022/2023640 60 76 8 45 117 79 16 41 100 8 82 8
2023/2024429 33 47 13 55 43 65 19 30 18 17 22 67
2024/20251.218 38 76 58 65 128 154 104 236 36 73 120 130
2025/2026545 270 66 96 108 5 0 0 0 0 0 0 0
Totale 6.010